FIELD: medicine.
SUBSTANCE: method of antidementia drug stabilisation, particularly donepezil or its pharmaceutically acceptable salt, includes the addition of high-molecular acidic substance. Besides the present invention offers a pharmaceutical composition containing an antidementia drug and high-molecular base substance, as well as a high-molecular acidic substance to ensure antidementia drug stabilisation. The invention presents a method of manufacturing of the pharmaceutical composition which involves the stages whereat a solution or a suspension containing the high-molecular acidic substance is added to the pre-mixed antidementia drug and high-molecular base substance for the purpose of antidementia drug stabilisation.
EFFECT: preparation of the stabilised antidementia drug.
20 cl, 11 tbl, 1 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION CONTAINING DEMENTIA DRUG | 2006 |
|
RU2445092C2 |
| SLOW-RELEASE MATRIX PREPARATION CONTAINING BASE AGENT OR ITS SALT AND METHOD FOR MAKING THEREOF | 2005 |
|
RU2390354C2 |
| DRUG DELIVERY SYSTEMS CONTAINING WEAKLY ALKALINE SELECTIVE 5-HT SEROTONINE ANTAGONIST AND ORGANIC ACIDS | 2007 |
|
RU2490012C2 |
| SYSTEMS OF MEDICATION DELIVERY, INCLUDING SOLID SOLUTIONS OF WEAK-BASE MEDICATIONS | 2007 |
|
RU2434630C2 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
| DRUG-RELEASING SYSTEM SHOWING SPECIFICITY TO LARGE INTESTINE | 1995 |
|
RU2155605C2 |
| SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION CONTAINING RIVASTIGMINE | 2016 |
|
RU2727721C2 |
| PHARMACEUTICAL FORM FOR DRUG DELIVERY TO THE COLON | 2007 |
|
RU2646825C2 |
| FORMULATIONS FOR ORAL DELIVERY OF ADSORBENTS IN INTESTINE | 2016 |
|
RU2681315C2 |
| PARTICULATE COMPOSITION AND PROCESS FOR OBTAINING IT | 2012 |
|
RU2648353C2 |
